美股A股
StockGist
Back
8-K2026-11-05· merged:deepseek-v4-flash

OMDA · Omada Health

0001628280-26-070989

SEC filing

Summary

Omada Q3营收$91M增34%、扭亏为盈净利$7M,糖尿病与高血压项目驱动会员达110万并上调全年指引。

Key takeaways

Full analysis

指标本期去年同期同比
Revenue$91.3M$68.0M34%
Gross Margin (GAAP)76%66%—
Gross Margin (Non-GAAP)78%68%—
Operating Income$4.8M$(2.5)M—
Net Income$6.6M$(3.2)M—
Diluted EPS (GAAP)$0.10$(0.06)—
Adjusted EBITDA$12.4M$2.4M—
Total Members1.1 million—36%
期间指标指引口径
FY2026Revenue$344M–$346MN/A
FY2026Adjusted EBITDA$32M–$34MNon-GAAP

本季增长由糖尿病与高血压项目驱动,服务收入$85.1M、硬件收入$6.2M,Total Members达1.1 million(同比+36%),平均会员留存升至约2年4个月(同比+10%),带动trailing 12-month revenue per Total Member同比增约5%至$294。GAAP毛利率由66%升至76%,Non-GAAP毛利率由68%升至78%,叠加经营杠杆,GAAP经营利润转正至$4.8M、净利润$6.6M,Adjusted EBITDA达$12.4M(margin 14%,去年4%)。

全年2026指引上调:营收$344M–$346M(前值$334M–$340M,中值约33%增长),Adjusted EBITDA $32M–$34M(前值$21M–$27M,中值约同比改善$27M、约5.5倍);公司未提供GAAP净利润指引及调节表。资产负债表端现金及等价物$243.2M,前九个月经营现金流$7.3M、自由现金流$2.5M均转正。需关注客户与渠道伙伴集中度、会员参与度及医疗监管合规等风险(详见Exhibit 99.1前瞻性声明)。